Dr Reddy’s Laboratories Ltd's (DRL) Q4 revenue growth remained soft with growth in various geographies being a mixed bag. The North American sales contributing 37% to overall earnings fell 3%.
This nevertheless was on a large base of last year. Q4 FY20 had seen much higher volumes due to covid-19 related stocking. The sequential growth of 1% despite new product launches, however, also failed to impress.
The company attributed the same to price erosion. And, hence, the street will be watchful on the impact of price erosion moving forward too.On the positive side, the company has a large range of products for the US markets.